Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

ALK+ Advanced NSCLC × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 6100 Lung Neoplasms 4518 Small Cell Lung Carcinoma 1010 Breast Neoplasms 752 Neoplasms 691 Colorectal Neoplasms 583 Melanoma 486 Ovarian Neoplasms 442 Neoplasm Metastasis 416 Pancreatic Neoplasms 415 Adenocarcinoma of Lung 355 Stomach Neoplasms 341 Prostatic Neoplasms 330 Head and Neck Neoplasms 320 Carcinoma, Renal Cell 302 Mesothelioma, Malignant 292 Esophageal Neoplasms 287 Squamous Cell Carcinoma of Head and Neck 283 Mesothelioma 259 Colonic Neoplasms 257 Urinary Bladder Neoplasms 232 Brain Neoplasms 224 Uterine Cervical Neoplasms 200 Triple Negative Breast Neoplasms 193 Sarcoma 173 Endometrial Neoplasms 171 Carcinoma, Hepatocellular 153 NSCLC 151 Carcinoma 142 Pleural Effusion, Malignant 140

Interventions

brigatinib 1 alectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03596866 2025-09-12

ALTA-3

Takeda

Phase 3 Completed

248 enrolled 20 charts

ALK+ Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡